DXI 9000
Device
Beckman Coulter, Inc.
Total Payments
$5.8M
Transactions
371
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $4.8M | 256 | 0 |
| 2020 | $985,808 | 115 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.8M | 371 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Blood Virus HIV (HIV-01-18) | Beckman Coulter, Inc. | $1.7M | 0 |
| HF-01-19 | Beckman Coulter, Inc. | $987,451 | 0 |
| Blood Virus HBV (HBV-01-18) | Beckman Coulter, Inc. | $891,710 | 0 |
| HF Pivotal (HF-01-19) | Beckman Coulter, Inc. | $723,040 | 0 |
| CHF-01-18, HF-01-19 | Beckman Coulter, Inc. | $268,116 | 0 |
| CHF-01-18 | Beckman Coulter, Inc. | $230,162 | 0 |
| Blood Virus HCV (HCV-01-18) | Beckman Coulter, Inc. | $212,950 | 0 |
| HF Ref Interval (CHF-04-18) | Beckman Coulter, Inc. | $212,918 | 0 |
| External Reliability Test Protocol | Beckman Coulter, Inc. | $161,618 | 0 |
| HF Feasibility (CHF-01-18) | Beckman Coulter, Inc. | $137,863 | 0 |
| HF-04-18 | Beckman Coulter, Inc. | $68,992 | 0 |
| DXI 9000 External Reliability | Beckman Coulter, Inc. | $63,823 | 0 |
| HF Feasibility (CHF-01-18) - CEC | Beckman Coulter, Inc. | $46,241 | 0 |
| HF Feasibility (BHF19) | Beckman Coulter, Inc. | $18,645 | 0 |
| HF Pivotal - CEC (BEH20) | Beckman Coulter, Inc. | $1,925 | 0 |
| HF Pivotal (HF-01-19) - CEC | Beckman Coulter, Inc. | $1,625 | 0 |
| HF-01-19 consulting | Beckman Coulter, Inc. | $1,200 | 0 |
Top Doctors Receiving Payments for DXI 9000
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Detroit, MI | $5.8M | 371 |
Ad
Manufacturing Companies
- Beckman Coulter, Inc. $5.8M
Product Information
- Type Device
- Total Payments $5.8M
- Total Doctors 0
- Transactions 371
About DXI 9000
DXI 9000 is a device associated with $5.8M in payments to 0 healthcare providers, recorded across 371 transactions in the CMS Open Payments database. The primary manufacturer is Beckman Coulter, Inc..
Payment data is available from 2020 to 2021. In 2021, $4.8M was paid across 256 transactions to 0 doctors.
The most common payment nature for DXI 9000 is "Unspecified" ($5.8M, 100.0% of total).
DXI 9000 is associated with 17 research studies, including "Blood Virus HIV (HIV-01-18)" ($1.7M).